Abstract Acute leukemia of ambiguous lineage (ALAL) is a rare, high-risk form of acute leukemia. It is characterized by the inability to assign a single lineage of differentiation to the leukemia and can manifest with more than one lineage-defining marker, called mixed phenotype…
Key Points: Many patients and caregivers associate early palliative care (EPC) with hospice or death, a misperception that may persist even after gaining a better understanding of the role of EPC and may prevent them from experiencing the benefits of EPC. Cultural or religious…
Abstract Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of hematologic malignancies, yet its application to acute myeloid leukemia (AML) remains challenging due to the scarcity of disease-specific antigens. The identification of a highly selective…
Key Takeaways Approval targets older/unfit newly diagnosed AML, introducing an all-oral HMA/venetoclax backbone that may reduce infusion burden and expand outpatient feasibility. ASCERTAIN‑V part B delivered DEC‑C days 1–5 q28d with venetoclax ramp-up to 400 mg then 400 mg daily…
Abstract Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). While genetic alterations can contribute to resistance, the role of rapid-adaptive non-genetic mechanisms, particularly transcription…
ABSTRACT Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective treatment for patients with high-risk hematologic malignancies. Over the last decade, gut microbiota composition during allo-HCT has been associated with patients' outcomes. Treatment-related…
On May 13, 2026, the U.S. Food and Drug Administration (FDA) approved an all-oral regimen of decitabine–cedazuridine (DEC-C; ASTX727) plus venetoclax for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy…
Key Points For patients with AML treated with LIT, ELN 2024 and Beat AML 2024 best identify a favorable group. Allogeneic stem cell transplant improves survival, but patients classified as adverse risk by any system still have poor outcomes. Abstract Real-world validation of the…
In this issue of Blood, Muffly et al1 demonstrate in a phase 1 trial the feasibility and safety of CD117-targeted, precision preconditioning for allogeneic hematopoietic cell transplantation (allo-HCT) in acute myeloid leukemia (AML) and myelodysplastic neoplasia (MDS). Almost 70…
